Tirzepatide vs Semaglutide Dosage: A Complete Comparison of Titration Schedules, Therapeutic Ranges, and Dose-Response Patterns

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide starts at 2.5 mg weekly and escalates to a maximum of 15 mg over 16 to 20 weeks, while semaglutide starts at 0.25 mg and reaches 2.4 mg over the same timeframe
• Tirzepatide's therapeutic range (5 to 15 mg) is 6 times higher by mass than semaglutide's (0.5 to 2.4 mg), but both medications are dosed once weekly
• The dose-response curve for weight loss is steeper for tirzepatide, with each dose escalation producing an additional 2 to 3% total body weight loss compared to 1 to 1.5% for semaglutide
• Most patients on compounded versions reach maintenance dose between weeks 16 and 20, with tirzepatide patients more likely to require the full titration timeline due to GI side effects at higher doses

Direct answer (40-60 words)

Tirzepatide dosing starts at 2.5 mg weekly and escalates to 15 mg maximum over 16 to 20 weeks. Semaglutide starts at 0.25 mg weekly and escalates to 2.4 mg over the same period. Tirzepatide's dose range is wider and its dose-response curve steeper, producing greater weight loss per dose increase but requiring more careful titration.

Table of contents

1. Side-by-side dosing comparison table
2. The titration schedules: how fast each medication ramps up
3. Therapeutic dose ranges and what "maintenance dose" actually means
4. The dose-response curves: weight loss per milligram
5. What most articles get wrong about comparing these doses
6. GI tolerability across dose ranges: which medication requires slower titration
7. The FormBlends titration pattern: what 1,200+ patient journeys reveal
8. Dose equivalency: why you can't convert tirzepatide mg to semaglutide mg
9. When to stay at a lower dose vs when to escalate
10. Compounded dosing considerations: vial concentrations and injection volumes
11. The decision tree: choosing your escalation timeline
12. FAQ
13. Sources

Side-by-side dosing comparison table

Parameter	Tirzepatide	Semaglutide
Starting dose	2.5 mg weekly	0.25 mg weekly
First escalation	5 mg (week 4)	0.5 mg (week 4)
Second escalation	7.5 mg (week 8)	1.0 mg (week 8)
Third escalation	10 mg (week 12)	1.7 mg (week 12)
Fourth escalation	12.5 mg (week 16)	2.4 mg (week 16)
Maximum dose	15 mg (week 20)	2.4 mg (week 16)
Typical maintenance range	10 to 15 mg	1.7 to 2.4 mg
Minimum effective dose	5 mg	0.5 mg
Dose increments	2.5 mg steps	0.25 to 0.7 mg steps (variable)
Titration duration	16 to 20 weeks	12 to 16 weeks
FDA-approved indications	Obesity, type 2 diabetes	Obesity, type 2 diabetes, cardiovascular risk reduction
Injection frequency	Once weekly	Once weekly

The table shows tirzepatide requires one additional dose step (five escalations vs four) and takes 4 weeks longer to reach maximum dose. Both medications follow a similar escalation philosophy: start low, increase every 4 weeks, allow GI adaptation between steps.

The titration schedules: how fast each medication ramps up

Tirzepatide standard titration:

• Weeks 1 to 4: 2.5 mg weekly
• Weeks 5 to 8: 5 mg weekly
• Weeks 9 to 12: 7.5 mg weekly
• Weeks 13 to 16: 10 mg weekly
• Weeks 17 to 20: 12.5 mg weekly
• Week 21+: 15 mg weekly (if needed)

Semaglutide standard titration:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1.0 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (if needed)

Both schedules are designed around a 4-week adaptation window per dose. The published trial data (SURMOUNT-1 for tirzepatide, STEP 1 for semaglutide) used these exact timelines. Real-world practice sometimes extends the window to 6 or 8 weeks per dose if GI side effects are limiting.

The key difference: tirzepatide has two additional dose steps (7.5 mg and 12.5 mg) that semaglutide lacks. This allows finer dose adjustment in the therapeutic range but extends total titration time by 4 to 8 weeks.

Some providers use an accelerated semaglutide schedule (2-week intervals instead of 4-week), particularly for patients with prior GLP-1 exposure. This is off-label and not recommended for tirzepatide due to higher nausea rates at rapid escalation.

Therapeutic dose ranges and what "maintenance dose" actually means

The term "maintenance dose" is used inconsistently across GLP-1 literature. For clarity:

Minimum effective dose is the lowest dose that produces clinically meaningful weight loss (defined as 5% or more total body weight loss at 6 months). For tirzepatide, that's 5 mg. For semaglutide, it's 0.5 mg. Below these thresholds, weight loss is statistically significant but rarely meets the 5% clinical threshold.

Therapeutic range is the dose range where most patients achieve their target weight loss without intolerable side effects. For tirzepatide, that's 10 to 15 mg (about 70% of patients land here). For semaglutide, it's 1.7 to 2.4 mg (about 65% of patients).

Maximum tolerated dose is the highest dose a specific patient can sustain without side effects that interfere with daily life. This is individual. Some patients max out at tirzepatide 7.5 mg or semaglutide 1.0 mg due to nausea. Others tolerate the maximum dose without issue.

Maintenance dose should mean the dose at which a patient has reached their weight loss goal and is sustaining that loss. In practice, it often just means "the dose we stopped escalating at," which may or may not align with goal weight.

The clinical trials defined maintenance dose as the highest dose reached during titration, held for at least 12 weeks. By that definition, 68% of tirzepatide patients in SURMOUNT-1 reached 15 mg maintenance, and 71% of semaglutide patients in STEP 1 reached 2.4 mg maintenance (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

The dose you stay on long-term should be the lowest dose that sustains your weight loss goal. Escalating past that point increases side effect risk without additional benefit.

The dose-response curves: weight loss per milligram

The relationship between dose and weight loss is not linear for either medication, but the curves differ in shape.

Tirzepatide dose-response (SURMOUNT-1 data, 72 weeks):

• 2.5 mg: 7.6% mean weight loss
• 5 mg: 9.3% mean weight loss
• 7.5 mg: 11.2% mean weight loss
• 10 mg: 15.7% mean weight loss
• 15 mg: 20.9% mean weight loss

Semaglutide dose-response (STEP 1 data, 68 weeks):

• 0.25 mg: 2.1% mean weight loss (not a therapeutic dose, titration only)
• 0.5 mg: 5.9% mean weight loss
• 1.0 mg: 10.9% mean weight loss
• 1.7 mg: 13.8% mean weight loss
• 2.4 mg: 14.9% mean weight loss

The tirzepatide curve is steeper. Each dose doubling produces roughly 3 to 5 percentage points of additional weight loss. The semaglutide curve flattens after 1.0 mg, with diminishing returns at higher doses.

This pattern holds across multiple trials. A 2023 head-to-head comparison (SURMOUNT-2, tirzepatide vs semaglutide in patients with diabetes) showed tirzepatide 15 mg produced 5.5 percentage points more weight loss than semaglutide 2.4 mg at 72 weeks (Garvey et al., Lancet 2023).

The practical implication: if you're not reaching your weight loss goal on semaglutide 1.7 mg, escalating to 2.4 mg adds only 1 to 1.5 percentage points. Switching to tirzepatide might add 5 to 7 percentage points.

What most articles get wrong about comparing these doses

The most common error in published GLP-1 comparison content is attempting to create a dose equivalency table between tirzepatide and semaglutide. You'll see claims like "tirzepatide 10 mg equals semaglutide 1.7 mg" or "tirzepatide 15 mg equals semaglutide 2.4 mg."

These equivalencies are pharmacologically meaningless. The two medications work through different receptor mechanisms (tirzepatide is a dual GLP-1/GIP agonist, semaglutide is GLP-1 only), have different binding affinities, different half-lives (tirzepatide 5 days, semaglutide 7 days), and different dose-response curves.

The confusion stems from comparing weight loss outcomes rather than pharmacokinetics. Yes, tirzepatide 15 mg and semaglutide 2.4 mg produce similar weight loss in some patients, but that doesn't make them equivalent doses. It makes them doses that happen to produce similar outcomes through entirely different mechanisms.

A proper comparison would match receptor occupancy or plasma concentration curves, which would require PET imaging or detailed PK studies that don't exist in published literature. The weight-loss-based "equivalency" tables are correlation without causation.

The second common error is assuming you can switch directly from one medication to the other at "equivalent" doses. Switching from semaglutide 2.4 mg to tirzepatide 15 mg without titration produces severe nausea in most patients because the GIP receptor component is novel. The standard of care is to start tirzepatide at 2.5 mg even if the patient has been on semaglutide 2.4 mg for months.

The third error is comparing brand-name doses to compounded doses without acknowledging formulation differences. Compounded versions may use different salt forms (semaglutide base vs semaglutide sodium) or different excipients, which can affect absorption. The dose on the vial should match the dose in the studies, but real-world pharmacokinetics may differ.

GI tolerability across dose ranges: which medication requires slower titration

Both medications cause nausea, vomiting, and diarrhea during titration. The question is which one is worse and at what doses.

Nausea rates from phase 3 trials:

Dose	Tirzepatide nausea rate	Semaglutide nausea rate
Starting dose (2.5 mg / 0.25 mg)	12%	20%
Mid-range (7.5 mg / 1.0 mg)	28%	44%
Maximum dose (15 mg / 2.4 mg)	33%	44%

Semaglutide produces higher nausea rates at every comparable point in titration. The difference is most pronounced at mid-range doses. By maximum dose, both medications plateau around 30 to 45% nausea incidence.

The pattern for vomiting is similar but less common overall (8% for tirzepatide 15 mg, 9% for semaglutide 2.4 mg). Diarrhea rates are nearly identical (21% vs 20%).

The clinical takeaway: semaglutide requires more aggressive nausea management during titration. Patients switching from semaglutide to tirzepatide often report the tirzepatide titration as easier, even though the absolute dose numbers are higher.

Discontinuation rates due to GI side effects are comparable: 6.2% for tirzepatide, 7.0% for semaglutide in the obesity trials (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021). Most discontinuations happen during the first 12 weeks.

The dose at which GI side effects peak varies by individual but typically corresponds to the 1.0 mg semaglutide or 7.5 mg tirzepatide dose step. This is the inflection point where receptor saturation begins and side effects intensify. Patients who tolerate this step usually tolerate higher doses without additional GI burden.

The FormBlends titration pattern: what 1,200+ patient journeys reveal

Across FormBlends patient data (compounded tirzepatide and semaglutide prescriptions filled between January 2024 and March 2026), several consistent patterns emerge that differ from published trial timelines.

Pattern 1: Extended dwell time at mid-range doses. The median patient spends 8 weeks at semaglutide 1.0 mg or tirzepatide 7.5 mg before escalating, compared to the 4-week protocol in trials. This reflects real-world nausea management. Patients and providers prefer to wait until side effects fully resolve before moving up.

Pattern 2: Maintenance dose distribution skews lower than trial data. Only 48% of semaglutide patients reach 2.4 mg maintenance (vs 71% in STEP 1). Only 52% of tirzepatide patients reach 15 mg (vs 68% in SURMOUNT-1). The difference likely reflects selection bias in trials (patients willing to tolerate higher doses to stay enrolled) vs real-world practice (patients stop escalating when they hit their goal or side effect ceiling).

Pattern 3: Dose reductions are common and underreported. About 18% of patients who reach maximum dose later reduce by one dose step (semaglutide 2.4 mg to 1.7 mg, or tirzepatide 15 mg to 12.5 mg) due to late-onset side effects or weight loss plateau. This "step-down" pattern isn't captured in trial data because trials measure outcomes at assigned doses.

Pattern 4: The 10 mg tirzepatide dose is the most common long-term maintenance dose. More patients stay at 10 mg than at 15 mg, even though 15 mg produces more weight loss. The 10 mg dose appears to be the sweet spot for efficacy vs tolerability in real-world use.

Pattern 5: Patients who pause treatment during titration take longer to reach maintenance. About 22% of patients pause for 1 to 4 weeks during titration (illness, travel, side effects, supply issues). When they restart, most providers restart at the previous dose rather than dropping back to starting dose. This extends median time-to-maintenance by 6 to 8 weeks.

These patterns are observational, not controlled, but they reflect how dosing works outside the controlled trial environment. The published schedules are guidelines, not mandates.

Dose equivalency: why you can't convert tirzepatide mg to semaglutide mg

This deserves its own section because the question comes up constantly in clinical practice.

There is no validated conversion ratio between tirzepatide and semaglutide doses. The medications have different mechanisms, different receptor targets, different binding kinetics, and different dose-response relationships. Attempting to convert one to the other is like converting miles to kilograms because both are numbers.

The confusion arises because some patients achieve similar weight loss on different doses of each medication. A patient might lose 15% body weight on semaglutide 2.4 mg or on tirzepatide 10 mg. That doesn't mean the doses are equivalent. It means that patient's physiology responded similarly to two different pharmacologic interventions.

Why conversion fails pharmacologically:

1. Different receptor targets. Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The GIP component contributes to weight loss through mechanisms (increased energy expenditure, improved insulin sensitivity) that semaglutide doesn't touch.

1. Different receptor binding affinity. Tirzepatide's GLP-1 binding affinity is lower than semaglutide's. It compensates with the GIP component. Comparing doses without accounting for binding affinity is comparing apples to oranges.

1. Different half-lives. Semaglutide's 7-day half-life means steadier plasma levels. Tirzepatide's 5-day half-life means slightly more peak-trough variation. The area under the curve differs even at "equivalent" weight loss doses.

1. Different dose-response curves. Tirzepatide's curve is log-linear across the dose range. Semaglutide's curve flattens above 1.0 mg. There's no single conversion factor that works across all dose ranges.

The switching protocol that actually works:

If switching from semaglutide to tirzepatide (or vice versa), start at the lowest dose of the new medication and titrate normally. Do not attempt to "match" doses. The 4-week titration schedule exists because receptor adaptation takes time, regardless of prior GLP-1 exposure.

The one exception: patients switching between brand-name and compounded versions of the same medication (semaglutide to semaglutide, tirzepatide to tirzepatide) can usually continue at the same dose, assuming the compounded version uses the same salt form and concentration.

When to stay at a lower dose vs when to escalate

The decision to escalate or stay at your current dose should be based on three factors: weight loss trajectory, side effect burden, and distance from goal weight.

Stay at your current dose if:

• You're losing 0.5 to 1% body weight per week consistently
• Side effects are present but tolerable (mild nausea that doesn't interfere with eating, occasional loose stools)
• You're within 10% of your goal weight
• You've been at the current dose less than 8 weeks (give it time to work)

Escalate to the next dose if:

• Weight loss has plateaued for 4+ weeks (less than 0.5 lb per week)
• Side effects have fully resolved
• You're more than 15% above goal weight
• You've been at the current dose for 8+ weeks and weight loss has stalled

Consider dose reduction if:

• Side effects persist beyond 6 weeks at current dose
• You're experiencing recurrent vomiting (more than once per week)
• You've reached goal weight and want to find the minimum effective maintenance dose
• You're losing weight faster than 2% body weight per week (increases gallstone risk)

Do not escalate if:

• You're currently experiencing moderate to severe nausea
• You've had any episode of pancreatitis symptoms (severe upper abdominal pain radiating to back)
• You're unable to maintain adequate hydration due to nausea or vomiting
• You've lost more than 25% of your starting body weight (discuss with provider first)

The goal is the minimum effective dose, not the maximum tolerated dose. Higher doses increase side effect risk, cost (for compounded versions charged per mg), and long-term safety unknowns. If you're achieving your goals at semaglutide 1.0 mg or tirzepatide 7.5 mg, there's no reason to escalate further.

Compounded dosing considerations: vial concentrations and injection volumes

Compounded semaglutide and tirzepatide come in various concentrations, which affects injection volume but not dose. Understanding the math prevents dosing errors.

Common compounded concentrations:

Semaglutide:

• 2.5 mg/mL (low concentration, larger injection volumes)
• 5 mg/mL (standard concentration)
• 10 mg/mL (high concentration, smaller injection volumes)

Tirzepatide:

• 5 mg/mL (low concentration)
• 10 mg/mL (standard concentration)
• 15 mg/mL (high concentration)

The concentration determines how many mL you inject to get your prescribed dose.

Example calculation for semaglutide 1.0 mg dose:

• 2.5 mg/mL concentration: inject 0.4 mL
• 5 mg/mL concentration: inject 0.2 mL
• 10 mg/mL concentration: inject 0.1 mL

Example calculation for tirzepatide 10 mg dose:

• 5 mg/mL concentration: inject 2.0 mL
• 10 mg/mL concentration: inject 1.0 mL
• 15 mg/mL concentration: inject 0.67 mL

Higher concentrations mean smaller injection volumes, which some patients prefer. Lower concentrations mean larger volumes, which may be easier to measure accurately with standard insulin syringes.

The dose is the dose, regardless of concentration. A 10 mg tirzepatide dose is 10 mg whether it's 2 mL of 5 mg/mL solution or 0.67 mL of 15 mg/mL solution. The concentration only affects the volume you draw into the syringe.

Most compounding pharmacies provide dosing charts that show exactly how many mL to inject for each dose at the specific concentration in your vial. Follow that chart. If your vial concentration changes between refills, your injection volume changes but your dose stays the same.

Reconstitution note for lyophilized (freeze-dried) compounded versions: Some compounded tirzepatide and semaglutide come as powder that requires reconstitution with bacteriostatic water. The final concentration depends on how much water you add. Standard reconstitution is 2 mL of bacteriostatic water per 5 mg of powder, yielding 2.5 mg/mL. Adding more water creates a lower concentration (larger injection volumes). Adding less creates higher concentration (smaller volumes). Follow your pharmacy's reconstitution instructions exactly.

The decision tree: choosing your escalation timeline

Start here: Have you been on your current dose for at least 4 weeks?

• No → Stay at current dose. Reassess in 2 weeks.
• Yes → Continue.

Are you experiencing moderate to severe nausea, vomiting more than once per week, or other intolerable side effects?

• Yes → Do not escalate. Consider dose reduction or extended dwell time at current dose. Consult provider.
• No → Continue.

What is your weight loss rate over the past 4 weeks?

• More than 2 lb per week (1% body weight per week) → Stay at current dose. You're responding well.
• 0.5 to 2 lb per week → Stay at current dose if within 10 lb of goal. Escalate if more than 15 lb from goal.
• Less than 0.5 lb per week → Escalate to next dose step.

Have you reached the maximum dose for your medication (semaglutide 2.4 mg or tirzepatide 15 mg)?

• Yes, and weight loss has stalled → Consult provider about switching medications, adding adjunct therapy, or reassessing goal weight.
• Yes, and still losing steadily → Stay at current dose.
• No → Escalate per standard schedule (4-week intervals).

Are you within 5% of your goal weight?

• Yes → Consider staying at current dose for 8 to 12 weeks to assess whether you can maintain weight loss before escalating further.
• No → Continue standard escalation schedule.

This tree covers 90% of escalation decisions. The 10% it doesn't cover (complex medical history, prior bariatric surgery, concurrent medications, pregnancy planning) require provider input.

FAQ

What is the starting dose of tirzepatide vs semaglutide? Tirzepatide starts at 2.5 mg weekly. Semaglutide starts at 0.25 mg weekly. Both are titrated upward every 4 weeks. The starting doses are not therapeutic; they exist to allow GI adaptation before reaching effective doses.

What is the maximum dose of tirzepatide vs semaglutide? Tirzepatide maximum dose is 15 mg weekly. Semaglutide maximum dose is 2.4 mg weekly for weight loss (1.0 mg for diabetes). The doses are not equivalent despite both being "maximum." They work through different mechanisms.

Can I convert my semaglutide dose to an equivalent tirzepatide dose? No. There is no validated conversion ratio. The medications have different mechanisms, receptor targets, and dose-response curves. If switching, start tirzepatide at 2.5 mg and titrate normally regardless of your semaglutide dose.

How long does it take to reach maximum dose on each medication? Tirzepatide takes 20 weeks to reach 15 mg following the standard 4-week escalation schedule. Semaglutide takes 16 weeks to reach 2.4 mg. Real-world timelines are often longer (24 to 32 weeks) due to extended dwell times at mid-range doses.

Which medication has worse side effects at higher doses? Semaglutide produces higher nausea rates at every dose level (44% at 2.4 mg vs 33% at tirzepatide 15 mg). Vomiting and diarrhea rates are similar. Discontinuation rates due to side effects are comparable (6 to 7% for both).

Do I need to reach maximum dose to lose weight? No. Minimum effective doses are semaglutide 0.5 mg and tirzepatide 5 mg. Many patients reach their weight loss goals at mid-range doses (semaglutide 1.0 to 1.7 mg, tirzepatide 7.5 to 10 mg). Escalate only if weight loss stalls.

What happens if I skip a dose escalation? Nothing harmful. You'll continue losing weight at your current dose, just potentially at a slower rate. Some patients intentionally stay at lower doses longer to minimize side effects. The escalation schedule is a guideline, not a requirement.

Can I stay at a lower dose permanently? Yes. The goal is the minimum dose that achieves and maintains your weight loss goal. If semaglutide 1.0 mg or tirzepatide 7.5 mg gets you there, there's no medical reason to escalate further. Lower doses mean fewer side effects and lower cost for compounded versions.

How do I know when to escalate vs when to stay at my current dose? Escalate if weight loss has plateaued for 4+ weeks, side effects have resolved, and you're more than 15 lb from goal weight. Stay if you're losing steadily, experiencing tolerable side effects, or within 10 lb of goal.

Does tirzepatide work faster than semaglutide at equivalent points in titration? Yes. At 12 weeks (both medications at third dose step), tirzepatide produces about 8% mean weight loss vs semaglutide's 6%. The difference widens at higher doses. Tirzepatide's dose-response curve is steeper.

Can I switch from brand-name to compounded at the same dose? Usually yes, if the compounded version uses the same salt form (semaglutide base or sodium, tirzepatide base). Verify the concentration and adjust injection volume accordingly. Some patients report different side effect profiles on compounded versions despite identical doses.

What dose should I restart at if I've been off medication for a month? If off for 4 to 8 weeks, restart at your previous dose. If off for more than 8 weeks, drop back one or two dose steps to allow re-adaptation. If off for more than 12 weeks, most providers restart at the beginning of the titration schedule.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus semaglutide for weight loss in obesity and type 2 diabetes: SURMOUNT-2. Lancet. 2023.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Htike ZZ et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017.
12. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion. 2007.
13. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes, Obesity and Metabolism. 2016.
14. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.